News

MPS VII is a progressive and debilitating inherited, rare genetic disease which previously didn’t have any approved therapy. It is a metabolic lysosomal storage disorder (LSD) resulting from

Fasenra has been approved as an add-on maintenance treatment for patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. The approval was based

Through these investments, executed over a multi-year period and capped recently in 2017, Purdue is establishing a portfolio of drug candidates with the potential to deliver new cancer

The American company had announced its plan to sell the business in July as it was anticipating that the upcoming drug distribution reform in China will affect its

 Both compounds are being investigated in global studies for the treatment of patients with cancers harboring tropomyosin receptor kinase (TRK) gene fusions, which are genetic alterations across a

The proceeds from this financing will be used for the advancement of Arcus’s clinical programs for AB928, a first-in-class dual adenosine receptor antagonist, and AB122, a PD-1 antibody.

Sawai America is the parent company of US generics drugmaker Upsher-Smith Laboratories (USL). The deal allows Sawai and Sumitomo to form a strategic alliance in the generic pharmaceuticals

OI is a debilitating disease for which there is no current treatment approved by the U.S. Food and Drug Administration (FDA) or the EMA. Mereo announced commencement of

The sensor in Abilify MyCite is ingestible and can also record when the patients had taken the pill. Abilify MyCite has been approved for treating schizophrenia, acute treatment